Stemline Therapeutics, Inc. , a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells and tumor bulk, today reported financial results for the quarter ended September 30, 2014 and provided a corporate update. Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "This third quarter marked an extremely productive period for Stemline as we initiated and are actively enrolling patients in trials with SL-401 in BPDCN and relapsed/refractory AML, as well as with SL-701 in adult brain cancer.
http://ift.tt/1sDWU0s
http://ift.tt/1sDWU0s
No comments:
Post a Comment